Rallybio Corp has taken significant steps towards its merger with Avenzo Therapeutics, as shareholders approved several key proposals during the annual meeting held on November 4, 2026. The approval of the merger is set to reshape the company's strategic direction and its position within the pharmaceutical preparations industry.

Rallybio Corp, trading under the ticker RLYB on the Nasdaq, specializes in pharmaceutical preparations, as classified under SIC 2834. The company, incorporated in Delaware, has been actively pursuing growth opportunities, and this merger with Avenzo Therapeutics is a pivotal move in that direction. Recent filings indicate that Rallybio has been preparing for this merger since May 31, 2026, when the Agreement and Plan of Merger was established.

The SEC filing reveals that the shareholders voted in favor of several proposals directly related to the merger. Notably, the stockholders approved the issuance of shares to Avenzo's securityholders, which will represent more than 20% of Rallybio's outstanding shares prior to the merger. This move is significant as it indicates a change of control within the company, aligning with Nasdaq Listing Rules.

The filing states, "The stockholders of record of the Company voted to approve the issuance of shares of the Company’s common stock... which will result in the change of control of the Company."

In addition to the share issuance, the stockholders also approved a reverse stock split of Rallybio's common stock at a ratio ranging from 1-for-2 to 1-for-9. This strategic decision is aimed at enhancing the company's stock performance and aligning it with the new corporate structure post-merger.

Another significant outcome of the meeting was the approval of the 2026 Equity Incentive Plan, which will replace the existing 2021 Plan. This new plan is contingent upon the completion of the merger and aims to incentivize employees and align their interests with those of the shareholders. The plan allows for the issuance of shares that could amount to 18% of the combined company’s stock post-merger, indicating a robust commitment to employee engagement and retention.

The approval of the 2026 Employee Stock Purchase Plan (ESPP) was also a highlight of the meeting. This plan will enable employees to purchase shares at a favorable rate, further fostering a sense of ownership among staff and enhancing morale as the company transitions into its new identity.

As part of the merger, Rallybio will also change its name to Avenzo Therapeutics, Inc., a move that reflects the new corporate identity and strategic focus. This name change was also approved during the stockholder meeting, signaling a fresh start for the combined entity.

The impact of these decisions will extend beyond Rallybio itself. The pharmaceutical preparations industry is poised for changes as the merger could lead to increased competition and innovation. Stakeholders, including employees, investors, and competitors, will be closely watching how this merger unfolds and what it means for the market dynamics in the coming months.

Looking ahead, the next steps involve finalizing the merger process and implementing the approved plans. The filing does not specify what happens next, but the momentum from the annual meeting suggests that Rallybio is gearing up for a transformative phase.